FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis

被引:12
|
作者
Chen, Gaoxiang [1 ]
Zhang, Jianan [1 ]
Teng, Weifeng [1 ]
Luo, Yong [1 ]
Ji, Xiaochun [1 ]
机构
[1] Ningbo Med Ctr Lihuili Hosp, Dept Thyroid & Breast Surg, 57 XingNing Rd, Ningbo, Zhejiang, Peoples R China
关键词
Thyroid cancer; Cuprotosis; FDX1; DLAT; Lipoylation;
D O I
10.1016/j.heliyon.2023.e18655
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cuprotosis is a recently identified cell death form that caused by intracellular copper accumulation and regulated by FDX1. This work aimed to explore the role of cuprotosis and the pivotal regulatory gene FDX1 in thyroid cancer development. We observed that expression of FDX1 in tumor section was notably lower than that in non-tumor sections in clinical samples. Induction of cuprotosis by elesclomol (ES) significantly repressed the in vitro and in vivo growth of thyroid cancer cells, simultaneously elevated Cu level and expression of FDX1, whereas depletion of FDX1 abolished these effects. Knockdown of FDX1 decreased the lipoylation level of DLAT and DLST in thyroid cancer cells, alleviated cuprotosis-induced cell death, simultaneously upregulated the levels of PA and & alpha;-KG. These findings demonstrated that FDX1 promotes the cuprotosis of thyroid cancer cells via regulating the lipoylation of DLAT.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Rab11a promotes the malignant progression of ovarian cancer by inducing autophagy
    Yazhuo Wang
    Yanan Ren
    Na Li
    Jing Zhao
    Sufen Zhao
    Genes & Genomics, 2022, 44 : 1375 - 1384
  • [32] Rab11a promotes the malignant progression of ovarian cancer by inducing autophagy
    Wang, Yazhuo
    Ren, Yanan
    Li, Na
    Zhao, Jing
    Zhao, Sufen
    GENES & GENOMICS, 2022, 44 (11) : 1375 - 1384
  • [33] TRIM50 inhibits glycolysis and the malignant progression of gastric cancer by ubiquitinating PGK1
    Gu, Chao
    Xia, Yiwen
    Lu, Chen
    Qiu, Shengkui
    Wang, Jihuan
    Zhang, Lu
    Lv, Jialun
    Jiang, Tianlu
    Fang, Lang
    Xu, Penghui
    Chen, Zetian
    Li, Ying
    Xie, Li
    Xu, Zekuan
    Li, Bowen
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20 (09): : 3656 - 3674
  • [34] Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma
    Xu, Jiahao
    Hu, Zhengang
    Cao, Hui
    Zhang, Hao
    Luo, Peng
    Zhang, Jian
    Wang, Xiaoyan
    Cheng, Quan
    Li, Jingbo
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer
    Zheng, W.
    Tian, X.
    Cai, L.
    Shen, Y-M
    Cao, Q-S
    Yang, J-Y
    Tian, G-Y
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (23) : 10443 - 10452
  • [36] Berberine inhibits prostate cancer progression by inducing ferroptosis: evidence from network pharmacology
    Zou, Peiliang
    Li, Shenghai
    He, Qixiong
    Zheng, Chixing
    ANTI-CANCER DRUGS, 2025, 36 (04) : 271 - 279
  • [37] Cryptolepine: A naturally derived alkaloid inhibits breast cancer progression by blocking cell cycle progression and inducing apoptosis
    Mir, Manzoor Ahmad
    Qayoom, Hina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP-J/NRF2/FDX1 pathway
    Zhang, Min-Jie
    Shi, Mengna
    Yu, Yang
    Ou, Rongying
    Ge, Ren-shan
    Duan, Ping
    MOLECULAR CARCINOGENESIS, 2024, 63 (08) : 1449 - 1466
  • [39] PIWIL1 Promotes Malignant Progression of Papillary Thyroid Carcinoma by Inducing EVA1A Expression (vol 24, pg 192, 2024)
    Liu, Lianyong
    Wu, Fengying
    Zhang, Xiaoying
    Li, Xiangqi
    CURRENT CANCER DRUG TARGETS, 2025, 25 (03) : 317 - 321
  • [40] ANK1 inhibits malignant progression of osteosarcoma by promoting ferroptosis
    Zhang, Fei
    Wan, Junming
    Zhong, Jinghua
    Mo, Jianwen
    BMC CANCER, 2024, 24 (01)